The immune system causes fear and psychedelies block the reaction

According to RCO News Agency, Research on the effects of psychotropicness has still made significant progress in the methods where mind changes can improve our health.

A new study last year showed that silosyebin is as effective as a commonly prescribed drug in reducing depression and in fact helps improve the overall quality of life compared to the drug. One study in year 4 showed that psychotropic substances were effective in improving the symptoms of mental health and the cognitive function of the damaged veterans. Even earlier, a study showed the role of these materials in improving long -term creative thinking.

Researchers at the University of Massachusetts General Brigam, by examining the role of psychotropics on our body, found that during chronic stress, our immune system introduced inflammatory cells called monocytes to amygdala, an area of ​​the brain that is responsible for processing our emotions, especially fear, anxiety and aggression. After arriving there, these cells stimulate the body’s fear reaction as well as the inflammatory signal.

Most interestingly, using mice models, the group found that silosyebin psychotropics prevent the accumulation of monocytes in the brain, thereby disrupting the immune system’s ability to create fear and inflammatory response.

“When chronic stress disrupts this signal, it results in a waterfall of processes that affect the static cells of the brain and immune cells and ultimately increase fear behavior,” says Michael Wheeler. The interesting thing is that psychotropic compounds can reverse the whole process.

Researchers also observed a similar response when examining human brain cells and gene expression data collected from patients with basic depression disorder (MDD), indicating that their findings could have consequences for the treatment of depression as well as fear -based disorders.

“Our study emphasizes how psychiatrics can do more than perceptual change,” says Wheeler. They can help reduce inflammation and reset brain interactions and immune systems. This can change our thinking about treating inflammatory disorders and conditions such as anxiety and depression.

Researchers say the discovery of this bond between the immune system’s ability to respond to fear and its disruption by psychotropics that had not been seen before, requires further research. They now intend to investigate how long -term use of psychotropics can affect patients with inflammatory diseases. They will do this by analyzing the tissue samples of patients in a clinical trial in which psychotropics are used to treat patients with depression.

Wheeler concludes: We do not say that psychotropics are treatment for inflammatory diseases or any other disease. But we see evidence that psychotropics have some special tissue benefits, and learning more about them can provide completely new facilities for the development of treatments.

The end of the message